Aethlon Medical Research Report.

SAN DIEGO -- Aethlon Medical, Inc., (OTCBB:AEMD) a pioneer in developing therapeutic devices for infectious disease, today disclosed that Marcus W. Robins, CFA, the lead analyst at Catalyst Financial Resources LLC, has initiated research coverage on the Company. The 14-page report, with disclosures can be accessed at:

http://catalystresearch.biz/ResearchAEMD.html

Mr. Robins is the Managing Partner and Founder of Catalyst Financial. Previously, Mr. Robins was Founder, Chief Executive Officer and Editor-In-Chief of The Red Chip Review, an independent research firm, and founder of RedChip Companies, LLC. Under his leadership, more than 10,000 research reports, analyst reviews, articles, white papers, and notes were written, published and distributed. Mr. Robins has been published in industry journals such as AAII, and Better Investing. He is a five-year small-cap columnist for Forbes Magazine. He previously co-managed the WestCap Small-cap Portfolio for Capital Consultants, Inc. in Portland, Oregon. While under his five-year co-leadership, WestCap grew to in excess of $100 million and he was named "Select Manager" in 1993 because of its returns and quality service. Mr. Robins has previously held positions of Portfolio Manager and Director of Research at several Portland, Oregon-based investment firms. He is past President of the Portland Society of Financial Analysts.

About Aethlon Medical

Aethlon Medical is developing the first medical device to treat infectious disease. The device, known as the Hemopurifier(TM), is a broad-spectrum treatment countermeasure against drug and vaccine resistant bioweapons, naturally evolving pandemic threats such as H5N1 Avian Flu, and chronic infectious disease targets including Hepatitis-C (HCV) and the Human Immunodeficiency Virus (HIV). Global researcher, Frost & Sullivan, recently awarded the Hemopurifier(TM) the 2006 Technology Innovation Award for its advances in the field of biodefense. Aethlon has also initiated research on a second generation Hemopurifier(TM) that targets the capture of growth factors inherent in the spread of Cancer. More information on Aethlon Medical and the Hemopurifier(TM) technology can be found at www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.